Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma

伦瓦提尼 医学 肝细胞癌 内科学 养生 耐受性 肿瘤科 不利影响 奥沙利铂 氟尿嘧啶 索拉非尼 胃肠病学 化疗 癌症 结直肠癌
作者
Minke He,Run-Bin Liang,Yang Zhao,Yu-Jie Xu,Huanwei Chen,Yuan-Min Zhou,ZhiCheng Lai,Li Xu,Wei Wei,Yaojun Zhang,Minshan Chen,Rong Guo,QiJiong Li,Ming Shi
出处
期刊:Therapeutic Advances in Medical Oncology [SAGE Publishing]
卷期号:13: 17588359211002720-17588359211002720 被引量:235
标识
DOI:10.1177/17588359211002720
摘要

Background: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and immune checkpoint inhibitors showed promising results for advanced hepatocellular carcinoma. Considering different anti-malignancy mechanisms, combining these three treatments may improve outcomes. This study aimed to compare the efficacy and safety of lenvatinib, toripalimab, plus HAIC versus lenvatinib for advanced hepatocellular carcinoma. Methods: This was a retrospective study including patients treated with lenvatinib [8 mg (⩽60 kg) or 12 mg (>60 kg) once daily] or lenvatinib, toripalimab plus HAIC [LeToHAIC group, lenvatinib 0–1 week prior to initial HAIC, 240 mg toripalimab 0–1 day prior to every HAIC cycle, and HAIC with FOLFOX regimen (oxaliplatin 85 mg/m 2 , leucovorin 400 mg/m 2 , 5-fluorouracil bolus 400 mg/m 2 on day 1, and 5-fluorouracil infusion 2400 mg/m 2 for 46 h, every 3 weeks)]. Progression-free survival, overall survival, objective response rate, and treatment-related adverse events were compared. Results: From February 2019 to August 2019, 157 patients were included in this study: 71 in the LeToHAIC group and 86 in the lenvatinib group. The LeToHAIC group showed longer progression-free survival (11.1 versus 5.1 months, p < 0.001), longer overall survival (not reached versus 11 months, p < 0.001), and a higher objective response rate (RECIST: 59.2% versus 9.3%, p < 0.001; modified RECIST: 67.6% versus 16.3%, p < 0.001) than the lenvatinib group. In addition, 14.1% and 21.1% of patients in the LeToHAIC group achieved complete response of all lesions and complete response of the intrahepatic target lesions per modified RECIST criteria, respectively. Grade 3/4 treatment-related adverse events that were more frequent in the LeToHAIC group than in the lenvatinib group included neutropenia (8.5% versus 1.2%), thrombocytopenia (5.6% versus 0), and nausea (5.6% versus 0). Conclusions: Lenvatinib, toripalimab, plus HAIC had acceptable toxic effects and might improve survival compared with lenvatinib alone in advanced hepatocellular carcinoma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘿嘿完成签到 ,获得积分10
刚刚
wang完成签到,获得积分10
刚刚
chengymao完成签到,获得积分10
刚刚
彭于晏的应助被炸薯条采纳,获得10
刚刚
刚刚
无事小神仙关注了科研通微信公众号
1秒前
sszz发布了新的文献求助10
1秒前
1秒前
科研通AI2S的应助被ZHI采纳,获得10
1秒前
安彤发布了新的文献求助10
2秒前
科研通AI6.4的应助被LONG采纳,获得10
2秒前
漂亮的访冬完成签到,获得积分10
2秒前
2秒前
2秒前
peekaboo完成签到,获得积分10
3秒前
kellyzzm发布了新的文献求助10
3秒前
震动的听安完成签到,获得积分10
3秒前
星河长明发布了新的文献求助20
4秒前
4秒前
透明的世界的应助被宿敌采纳,获得10
4秒前
Clover04的应助被萌萌大头菜采纳,获得10
4秒前
lincn发布了新的文献求助10
4秒前
qq完成签到,获得积分10
4秒前
苗子发布了新的文献求助10
5秒前
5秒前
5秒前
5114发布了新的文献求助10
5秒前
5秒前
Katherine发布了新的文献求助10
5秒前
Zzz完成签到,获得积分10
6秒前
务实寄松发布了新的文献求助10
6秒前
刻苦老三发布了新的文献求助10
6秒前
7秒前
7秒前
CipherSage的应助被35采纳,获得10
7秒前
外向丹南完成签到,获得积分10
7秒前
1234567完成签到,获得积分20
7秒前
西海岸第一rapper完成签到,获得积分10
7秒前
嘉佳完成签到,获得积分10
7秒前
文艺代灵完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180927
求助须知:如何正确求助?哪些是违规求助? 9570973
关于积分的说明 21815578
捐赠科研通 7777227
什么是DOI,文献DOI怎么找? 3433367
关于科研通互助平台的介绍 2557621
邀请新用户注册赠送积分活动 2479346